Association analysis of ACE, ACTN3 and PPARGC1A gene polymorphisms in two cohorts of European strength and power athletes.
Association analysis of ACE, ACTN3 and PPARGC1A gene polymorphisms in two cohorts of European strength and power athletes.
复制标题
ACE，ACTN3和PPARGC1A基因多态性的关联分析在两个欧洲力量和权力运动员中。
DOI：
10.5604/20831862.1201051
复制
发表时间：
2016-09
期刊：
影响因子：
5.6
通讯作者：
Utkus A
中科院分区：
文献类型：
--
作者：
Gineviciene V;Jakaitiene A;Aksenov MO;Aksenova AV;Druzhevskaya AM;Astratenkova IV;Egorova ES;Gabdrakhmanova LJ;Tubelis L;Kucinskas V;Utkus A
专业力量和力量运动员的表现至少部分地受到遗传成分的影响。本研究的主要目的是在两个队列的欧洲运动员中单独和联合研究ACE（I/D）、ACTN 3（R577 X）和PPARGC 1A（Gly 482 Ser）基因多态性与力量/力量导向运动员状态的相关性。来自俄罗斯和立陶宛的一组欧洲高加索人（161名运动员：按组-举重运动员（87名），举重运动员（60名），投掷运动员（14名）;按精英状态-“精英”（104名），“亚精英”（57名）;和1，202名对照）进行ACE，ACTN 3和PPARGC 1A多态性基因分型。采用聚合酶链反应和/或限制性片段长度多态性分析进行基因分型。与对照组相比，ACTN 3（R577 X）等位基因/基因型分布在整个运动员队列或分析组之间均未观察到统计学显著差异。俄罗斯队列中ACE I/I基因型运动员与对照组相比的优势比为1.71（95%CI 1.01-2.92），立陶宛队列中ACE I/D基因型运动员与对照组相比的优势比为2.35（95%CI 1.10-5.06）。PPARGC 1A Ser/Ser基因型携带者成为举重运动员的优势比为2.11（95%CI：1.09-4.09，P = 0.026）。ACTN 3（R577 X）多态性与两组欧洲运动员的力量/力量运动状态无关。ACE I/I基因型可能是俄罗斯运动员和立陶宛力量/力量运动员的ACE I/D基因型的“优选基因型”。我们发现PPARGC 1A（Gly 482 Ser）多态性与力量/力量运动员状态相关。具体而言，PPARGC 1A Ser/Ser基因型与对照组相比更有利于动力举重运动员。
The performance of professional strength and power athletes is influenced, at least partly, by genetic components. The main aim of this study was to investigate individually and in combination the association of ACE (I/D), ACTN3 (R577X) and PPARGC1A (Gly482Ser) gene polymorphisms with strength/power-oriented athletes’ status in two cohorts of European athletes. A cohort of European Caucasians from Russia and Lithuania (161 athletes: by groups – weightlifters (87), powerlifters (60), throwers (14); by elite status – ‘elite’ (104), ‘sub-elite’ (57); and 1,202 controls) were genotyped for ACE, ACTN3 and PPARGC1A polymorphisms. Genotyping was performed by polymerase chain reaction and/or restriction fragment length polymorphism analysis. Statistically significant differences in ACTN3 (R577X) allele/genotype distribution were not observed in the whole cohort of athletes or between analysed groups separately when compared with controls. The odds ratio for athletes compared to controls of the ACE I/I genotype was 1.71 (95% CI 1.01-2.92) in the Russian cohort and for the ACE I/D genotype it was 2.35 (95% CI 1.10-5.06) in the Lithuanian cohort. The odds ratio of being a powerlifter in PPARGC1A Ser/Ser genotype carriers was 2.11 (95% CI: 1.09-4.09, P = 0.026). The ACTN3 (R577X) polymorphism is not associated with strength/power athletic status in two cohorts of European athletes. The ACE I/I genotype is probably the ‘preferable genotype’ for Russian athletes and the ACE I/D genotype for Lithuanian strength/power athletes. We found that the PPARGC1A (Gly482Ser) polymorphism is associated with strength/power athlete status. Specifically, the PPARGC1A Ser/Ser genotype is more favourable for powerlifters compared to controls.